Clinical trials: Major Depressive Disorder (MDD)
Epilepsy, Major Depressive Disorder (MDD)
Lethargic Depression Study
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
- Trial name
- NCT00064467
- Testing
- Extended-release bupropion (HCl)
- Where
- 24 sites in United States
- Volunteers
- 268 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Depression Study In Elderly Patients
Major Depressive Disorder (MDD) Study in Elderly Outpatients
- Trial name
- NCT00067444
- Testing
- Paroxetine CR
- Where
- 46 sites in United States
- Volunteers
- 560 people
- Sponsor
- GlaxoSmithKline
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.
- Trial name
- NCT01912196
- Testing
- MSI-195
- Where
- 35 sites in United States
- Volunteers
- 376 people
- Sponsor
- MSI Methylation Sciences, Inc.
Major Depressive Disorder (MDD)
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding…
- Trial name
- NCT02012218
- Testing
- ADT, Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 61 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics…
- Trial name
- NCT00330616
- Testing
- 323U66 SR
- Where
- 9 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Study Of GW679769 In Major Depressive Disorder
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
- Trial name
- NCT00102492
- Testing
- GW679769
- Where
- 31 sites in United States, Canada
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with…
- Trial name
- NCT00960986
- Testing
- Duloxetine hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD).
- Trial name
- NCT00839176
- Testing
- RX-10100
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Depressive Disorder, Major, Major Depressive Disorder (MDD)
A Local Register Study For Major Depression Of Paroxetine Controlled Release
The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to Paroxetine Immediate Release, as well as the drug tolerability profile when treated on patients with Major Depression.
- Trial name
- NCT00368303
- Testing
- Paroxetine CR, Paroxetine IR
- Where
- 11 sites in China
- Volunteers
- 362 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, MDD
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study.
- Trial name
- Improve (NCT01344733)
- Where
- 29 sites in Italy
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Patient Tolerability Study of GSK163090
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
- Trial name
- NCT00559299
- Testing
- GSK163090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Effects of Antidepressants on Sexual Functioning
The purpose of this trial is to study the effects of two depression medications on sexual functioning.
- Trial name
- NCT00051259
- Testing
- Extended-Release Bupropion Hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
- Trial name
- NCT00057239
- Testing
- Radafaxine
- Where
- 29 sites in United States
- Volunteers
- 546 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.